Stockreport

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

BridgeBio Oncology Therapeutics, Inc.  (BBOT) 
PDF Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Ka, strongly inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows [Read more]